ReviewAnnals of surgical oncology2026
Neoadjuvant Chemoimmunotherapy versus Chemoradiotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Systematic Review and Reconstructed Individual Patient Data Meta-Analysis.
Review in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeoadjuvant chemoradiotherapy (NCRT) plus surgery is standard for resectable locally advanced esophageal squamous cell carcinoma (LA-ESCC), but survival remains suboptimal. Neoadjuvant chemoimmunotherapy (NCIT) is an emerging alternative. This meta-analysis compared efficacy, safety, and survival between NCIT and NCRT. MATERIALS AND
methodsProspective trials on NCIT or NCRT for resectable LA-ESCC were searched up to 17 March 2026. Pathological complete response (pCR), major pathological response (MPR), overall survival (OS), and progression-free survival (PFS) were assessed. Survival data were reconstructed from Kaplan-Meier curves, and one-stage meta-analysis using shared-frailty Cox models was performed.
resultsA total of 34 studies (1275 NCIT, 1045 NCRT patients) were included. NCIT significantly improved OS (HR 0.63, 95% CI 0.47-0.84) and PFS (HR 0.69, 95% CI 0.51-0.93). The 3-year OS rates were 74.7% (NCIT) versus 63.2% (NCRT); 3-year PFS rates were 65.7% versus 54.6%. Adjuvant immunotherapy further improved survival (OS HR 0.51, 95% CI 0.32-0.83). pCR (31% versus 39%) and MPR (55% versus 64%) were lower with NCIT (P < 0.05). Among NCIT patients, MPR predicted better OS (HR 0.27, 95% CI 0.13-0.57). Neoadjuvant treatment with 3-4 cycles was associated with a significantly higher pCR rate compared with 2 neoadjuvant cycles (41% versus 26%, P < 0.001). Among studies using two neoadjuvant cycles, the nab-paclitaxel backbone improved pCR (32% versus 19%) and MPR (59% versus 34%) compared with paclitaxel. Postoperative anastomotic leakage was lower with NCIT (7% versus 12%), while pneumonia and 90-day mortality were comparable.
conclusionsNCIT provides superior survival and a manageable safety profile compared with NCRT in resectable LA-ESCC. Neodjuvant immunotherapy extending to 3-4 cycles and adding adjuvant immunotherapy may enhance outcomes. Long-term RCTs are warranted.
Indexed as
Identifiers
42778840What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.